Protherics says revenue grew 27% in fiscal year
Protherics Plc, which focuses on specialist products for critical care and cancer, reported trading revenues of £23.5 million for the year ended 31 March 2008, up by 27% from the previous period.
News
The EMEA briefs journalists on the changing regulatory paradigm
There has been a gradual, but fundamental shift in the way regulatory agencies interact with the pharmaceutical industry, so that it is now commonplace for companies to meet with regulators before drug development gets into full swing.
Ipsen strengthens its position in the US with acquisitions
Ipsen SA has announced three separate deals to acquire assets in the US relating to the fields of endocrinology, neuromuscular disorders and haematology.
Novartis acquires rights to new broad-spectrum antibiotic
Novartis has acquired rights to a new broad-spectrum antibiotic currently in Phase 2 development in connection with its takeover of the product’s owner, Protez Pharmaceuticals of Malvern, Pennsylvania.
Change of strategy at MediGene
The German biotechnology company, MediGene AG, has reassessed its business strategy and decided to concentrate its resources on developing drugs in the fields of oncology and immunology. It plans to partner or divest its dermatology products.
More positive opinions from the EMEA
The European Medicines Agency (EMEA) is recommending that marketing authorisations be granted for new treatments for neuromuscular block and nosocomial pneumonia. It also recommended that extensions of indications for three marketed cancer drugs be approved.
Regenerative medicine opens up ‘transformational’ possibilities
Experts in the field of regenerative medicine recently met in London amid a mood of optimism.
4SC acquires stake and takeover option for Nexigen
The Munich-based drug development company, 4SC AG, has acquired a takeover option as well as a small stake in Nexigen GmbH, a spin-out company of the Bonn-based Center of Advanced European Studies and Research.
RNAi therapeutics attracts a new participant
Alnylam Pharmaceuticals, Inc of Cambridge, Massachusetts has concluded a new technology transfer and research alliance in the field of RNA interference (RNAi) therapeutics, confirming the importance of this technology for future drug development.
Two drug applications are withdrawn from the EMEA
Two drug applications that were under review by the European Medicine Agency’s main scientific committee have been withdrawn by their sponsors following the committee’s request for more data.